Aimovig Approval History
Reviewed on May 18, 2018 by J.Stewart B.Pharm.
- FDA approved: Yes (First approved May 17th, 2018)
- Brand name: Aimovig
- Generic name: erenumab-aooe
- Dosage form: Injection
- Company: Amgen Inc.
- Treatment for: Migraine Prevention
Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine.
Dosage and Administration
- Aimovig is a subcutaneous injection supplied as a 70 mg/mL solution in a single-dose prefilled SureClick® autoinjector or single-dose prefilled syringe.
- The recommended dosage is 70 mg once monthly, although some patients may benefit from a dosage of 140 mg once monthly (administered as two consecutive injections of 70 mg each).
- The needle shield within the white cap of the prefilled autoinjector and the gray needle cap of the prefilled syringe contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.
- The injection should be administered subcutaneously into the abdomen, thigh, or upper arm.
The most common adverse reactions in Aimovig clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation.
Development History and FDA Approval Process for Aimovig
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.